Manual_digital

363 / 510

Cuidados
Continuos
362
BIBLIOGRAFÍA
Tuca A, Jimenez-Fonseca P, Gascón P. Clinical evaluation and optimal management of cancer
cachexia. Crit Rev Oncol Hematol 2013;88(3):625-36.
Segura A, Pardo J, Jara C, Zugazabeitia L, Carulla J, De Las Peñas R, et al. An epidemiological
evaluation of the prevalence of malnutrition in Spanish patients with locally advanced or
metastatic cancer. Clin Nutr 2005; 24(5): 801-814.
Evans WJ, Morley JE, Argilés J, Bales C, Baracos V, Guttridge Dc, et al. Cachexia: a new
definition. Clin Nutr 2008; 27(6):793-9.
Paiva SI, Borges LR, Halpern-Silveira D, Assunçao MC, Barros AJ, Gonzalez MC. Standardized
phase angle from bioelectrical impedance analysis as prognostic factor for survival in patients
with cancer. Support Care Cancer 2010;19(2):187-92.
Prado CM, Lieffers JR, McCargar LJ et al. Prevalence and clinical implications of sarcopenic
obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population
based study. Lancet Oncology 2002;26(7):953-60.
Prado CM, Baracos VE, McCargar et al. Sarcopenia as a determinant of chemotherapy toxicity
and time tumor progression in mestastatic breast cancer patients recieving capecitabine
treatment. Clin Cancer Res 2009;15(8):2920-6.
Blum D, Omlin A, Fearon K, Baracos V, Radbruch L, Kaasa S, et al. Evolving classification
systems in cancer cachexia: ready for clinical practice?. Support Care Cancer 2010; 18:273-9.
J Fonseca, P., Álvarez, B. Comer para vencer el cáncer. Ed Nobel. 2012.
Jiménez-Fonseca, P., Martínez Cano, S. Remedios naturales para síntomas habituales. Ed
Nobel. 2013. pp 135-42.
Jiménez-Fonseca, P. Alimentación: Dieta recomendada después del cáncer. En: Todo lo que
empieza cuando “termina” el cáncer. Manual para supervivientes de cáncer y sus familiares.
Grupo Español de Pacientes con Cáncer (GEPAC), 2013. pp.205-19.
Maddedu C, Maccio A, Panzone F, Tanca FM, Mantovani G. Medroxyprogesterone acetate in the
management of cancer cachexia. Expert Opin Pharmacother 2009; 10(8):1359-66.
Lesniak W, Bała M, Jaeschke R, Krzakowski M. Effects of megestrol acetate in patients with
cancer anorexia-cachexia syndrome –a systematic review and meta-analysis. Pol Arch Med
Wewn. 2008; 118(11): 636-644.
Pascual López A, Roqué i Figuls M, Urrútia Cuchi G, Berenstein EG, Almenar Pasies B, Balcells
Alegre M, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia
syndrome. J Pain Symptom Manage 2004; 27(4): 360-369.
Berenstein EG, Ortiz Z. Acetato de megestrol para el tratamiento del síndrome anorexia-
caquexia (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008, n.º4. Oxford:
Update Software Ltd. Disponible en: (Traducida de: The
Cochrane Library, 2008, issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, et al. Randomized
comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the
treatment of cancer anorexia/cachexia. J Clinl Oncol. 1999; 17(10): 3.299-3.306.
1.
2.
3.
4.
5.
6.
7.
8.
9.
11.
12.
13.
14.
15.